Last reviewed · How we verify
Multivalent Group B streptococcus vaccine (multivalent-group-b-streptococcus-vaccine)
At a glance
| Generic name | multivalent-group-b-streptococcus-vaccine |
|---|---|
| Sponsor | Pfizer Inc. |
| Modality | Vaccine |
| Phase | Phase 3 |
Approved indications
Common side effects
- Fatigue (FATIGUE)
- Injection site pain (PAIN)
- Headache (HEADACHE)
- Myalgia (MUSCLE PAIN)
- Injection site pain
- Diarrhoea (DIARRHEA)
- Headache
- Fatigue
- Arthralgia (JOINT PAIN)
- Vomiting (NAUSEA/VOMITING)
- Injection site erythema (REDNESS)
- Myalgia
Key clinical trials
- BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies (PHASE3)
- Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Nonpregnant Women And Pregnant Women And Their Infants (PHASE2)
- Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women (PHASE2)
- A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Multivalent Group B streptococcus vaccine CI brief — competitive landscape report
- Multivalent Group B streptococcus vaccine updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI